NSAIDs to Prevent Breast Cancer Recurrence? An Unanswered Question
Mené sur 1 622 patientes atteintes d'un cancer du sein HR+ après la ménopause, cet essai randomisé évalue l'efficacité, du point de vue de la survie sans événement, de la survie sans récidive distante et de la survie globale, d'un traitement combinant célécoxib et faibles doses d'aspirine (durée médiane de suivi : 4,1 ans)
A large body of evidence spanning preclinical, observational, and clinical data supports the potential use of nonsteroidal anti-inflammatory agents (NSAIDs) for cancer prevention, and possibly as adjuncts to cancer treatment. NSAIDs hold great appeal in this regard because they are relatively safe and inexpensive, and aspirin offers the potential to prevent, treat, or palliate several common, chronic, age-related diseases (eg, prevention of cardiovascular events, cancer risk reduction, treatment of inflammatory conditions, pain management). To date, data supporting NSAID use for cancer risk reduction have been most compelling and consistent for colorectal cancer (CRC), where celecoxib and aspirin have shown efficacy in reducing the incidence of precancerous polyps and in reducing polyp/CRC incidence and mortality, respectively (1–3).